News

Samus Therapeutics Presents Phase 1 PU-AD Study Results at AAIC 2020 Advancing the Company’s Platform for Treating Neurodegenerative Diseases

July 29, 2020

Download PDF

Samus Therapeutics to Present at BIO CEO & Investor Conference

February 4, 2020

Download PDF

Study Published in Nature Communications Highlights the Role of the Epichaperome in Protein Connectivity-based Dysfunction in Alzheimer’s Disease

February 4, 2020

Download PDF

Samus Therapeutics Announces Presentation of Phase 1b Study Evaluating Orally Administered PU-H71 with Ruxolitinib in Myelofibrosis at the ASH 2019 Annual Meeting

December 9, 2019

Download PDF

Samus Therapeutics Announces Presentation of PU-AD Phase 1 Data for Alzheimer’s Disease at CTAD Congress

December 5, 2019

Download PDF

Samus Therapeutics Launches PU-AD Clinical Program in Alzheimer’s Disease

July 23, 2019

Download PDF

Samus Therapeutics Announces PU-H71 Granted Orphan Drug Designation and First Patient Dosed in Phase 1b Study in Myelofibrosis

June 13, 2018

Download PDF

Samus Therapeutics Announces Launch of Expanded Clinical Development Programs for Novel Anti-Epichaperome Small Molecules to Diagnose and Treat Cancer and Neurodegenerative Disease

March 30, 2017

Download PDF